24/7 Market News Snapshot 23 April, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

April 23, 2025

DENVER, Colo., 23 April, 2025 (www.247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp. (NASDAQ:SLXN) has witnessed remarkable growth today, with shares surging by 58.04% from an opening price of $0.759 to a current value of $1.111. This dramatic increase follows a closing price of $0.703 yesterday and has been accompanied by a substantial trading volume of 6.11 million shares, highlighting significant investor interest. Market analysts are closely monitoring this momentum as SLXN continues to establish its presence in the pharmaceutical sector, backed by strong technical indicators suggesting a bullish outlook.

In a strategic move to bolster its development pipeline, Silexion has announced a collaboration with Catalent, a leader in advanced delivery technologies and manufacturing solutions. This partnership focuses on the enhancement of Silexion’s promising siRNA candidate, SIL204, which is aimed at treating KRAS-driven cancers. Catalent will spearhead formulation development and clinical manufacturing activities, optimizing systemic and intratumoral delivery methods as part of Silexion’s innovative dual-route development strategy.

Recent preclinical results have revealed that SIL204 effectively hinders primary tumor growth and metastatic spread in pancreatic cancer models. The therapeutic candidate targets a broad spectrum of KRAS mutations, positioning it as a potential treatment option for various cancers, including pancreatic, colorectal, and lung cancers.

Ilian Hadar, the Chairman and CEO of Silexion, expressed optimism regarding the collaboration: “This partnership with Catalent represents a critical advancement for our SIL204 program. We are keen to leverage Catalent’s expertise as we refine SIL204’s formulation, aiming to initiate human clinical trials in the first half of 2026.”

As Silexion approaches additional toxicology and pharmacodynamic studies leading up to regulatory submissions anticipated in late 2025 and early 2026, this collaboration underscores the company’s dedication to pioneering innovative oncology therapies that could significantly improve patient outcomes.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.